Why Royal Dutch Shell Plc, AstraZeneca plc and Antofagasta plc Should Lag The FTSE 100 Today

Royal Dutch Shell Plc (LON: RDSB), AstraZeneca plc (LON: AZN) and Antofagasta plc (LON: ANTO) are having a down day.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The FTSE 100 (FTSEINDICES: ^FTSE) is retreating a little after five sessions of rises in a row, losing 32 points to 6,746 by noon. Although London’s top index has been buoyed in recent days by positive earnings, disappointing results from some of its star members lie behind today’s reversal.

We take a look at three companies holding the FTSE 100 back today:

Royal Dutch Shell

A disappointing performance miss from Royal Dutch Shell sent its shares down 109p (4.8%) to 2,168p this morning. Third-quarter earnings on a current-cost-of-supplies (CCS) basis crashed 32%, to $4.2bn from $6.2bn a year previously — a fall had been expected, but not one that big.

Also on a CCS basis, earnings per share excluding exceptional items fell 32% from a year ago, to 71 cents per share — but Shell’s quarterly dividend has been raised 5% to 45 cents per share.

Chief executive Peter Voser said “We are facing headwinds from weak industry refining margins, and the security situation in Nigeria, which continue to erode the near term outlook“, but reiterated that Shell is committed to rewarding its shareholders through dividends.

AstraZeneca

A third-quarter update from AstraZeneca also caused disappointment, with loss of exclusivity on several drug brands leading to an expected 4% fall in revenue to $6,250m. But that fall, compounded with increased research investment, led to a 20% fall in pre-tax profit to $1,592m and a 16% drop in earnings per share to 99 cents.

But on the upside, the company told us its late-stage pipeline is continuing to grow, with candidates olaparib, selumetinib and benralizumab all progressing to the Phase III clinical programme stage.

Today’s drop takes AstraZeneca shares to a P/E of 10.6 based on full-year forecasts — with a 5.5% dividend yield predicted, could they be a bargain now?

Antofagasta

Our third FTSE 100 faller today is Antofagasta (LSE: AZN), after investors reacted negatively to the copper miner’s Q3 production report.

Volumes of the brown metal were in line with expectations, with 174,200 tonnes of the stuff produced in the quarter — 3.4% down on the previous quarter, but 4.4% up year-to-date. And though output fell 11.7% on the quarter to 67,700 ounces, year-to-date production rose 8% to 230,600 ounces.

Forecasts for the full year are unchanged, but fears of a surplus of copper over the next few years pushing prices down further is what hit the share price today.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Alan does not own any shares mentioned in this article.

More on Investing Articles

artificial intelligence investing algorithms
Investing Articles

I asked Google AI for the best UK stocks for me to buy for 2025. Here are 5 names it gave me

Dr James Fox turned to artificial intelligence to explore the best UK stocks to buy in 2025. Here’s what Google’s…

Read more »

Investing Articles

2 no-brainer growth shares to consider in 2025!

These FTSE 100 and FTSE 250 growth shares delivered impressive share price gains in 2024. I think they should continue…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

How much would an investor need in an ISA for £800 in monthly passive income?

Generating a healthy dollop of monthly passive income need not remain a pipe dream. Paul Summers has whipped out his…

Read more »

Investing Articles

Has Tesla stock had its best days already?

Tesla stock has jumped around 70% in just a couple of months. Our writer likes the business -- but he's…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

In 3 steps, a new investor could start buying shares with just £500

Christopher Ruane outlines a trio of moves he thinks someone with a spare few hundred pounds could consider if they…

Read more »

Investing Articles

Up 513%! Can the Rolls-Royce share price  keep soaring in 2025?

Our writer sees reasons why the Rolls-Royce share price could go either way this year. Here's why he has no…

Read more »

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

£10,000 invested in Nvidia stock in 2020 would now be worth £244k! Here’s what could be next

Nvidia stock’s dominated the ‘picks and shovels’ market for artificial intelligence, but Dr James Fox believes it could be primed…

Read more »

Investing Articles

Next shares: the best FTSE 100 stock money can buy?

Next shares have performed brilliantly in recent years. Today's numbers suggest this momentum could continue into 2025, thinks Paul Summers.

Read more »